[Treatment of hypertension in a clinical trial. Depot alpha 1 blocker simplifies dosing].
Sauerbrey-Wullkopf
N
N
Klinische Forschung, Pfizer Deutschland, Postfach 4949, D-76032 Karlsruhe. norbert.sauerbrey-wullkopf@pfizer.com
Leverkus
F
F
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D017292:Doxazosin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D017292:Doxazosin